Expert voices from planning, health, government and consultants have shared their insights of using Health Impact Assessments as a force for good to create healthier new communities.
New research could give hope to patients with blood disorders such as leukaemia, thanks to a £1.7 million grant from Cancer Research UK.
The majority of women who have survived a cancer diagnosed age 15-39 are at low risk of obstetric complications, a new study has found.
The University of Bristol's Cancer Research Network hosted its third annual symposium dedicated to early career researchers on 18 June 2024. The event showcased the extraordinary and diverse research in cancer being conducted across Bristol and the South-West.
Two Bristol academics, Professors Eugenia Piddini and Gene Feder OBE, have been elected to the Academy of Medical Sciences’ respected and influential Fellowship. They join 58 exceptional biomedical and health scientists selected for their exceptional contributions to the advancement of medical science.
Dynamic Therapeutics, a University of Bristol spin-out, has today [25 April] been awarded a prestigious Blavatnik Prize by QantX, a leading venture capital firm, for its pioneering U-RHYTHM technology. The award recognises the scientific advances and future potential of the UK's most innovative scientists and engineers.
Three medical students are solving the shocking disparity in skin cancer care between those with dark skin and those with white skin.
The largest study to date investigating a single invitation to a PSA blood test to screen for prostate cancer has found it had a small impact on reducing deaths, but also led to overdiagnosis and missed early detection of some aggressive cancers. The CAP trial, published in the Journal of the American Medical Association (JAMA) and carried out by researchers from the universities of Bristol, Oxford and Cambridge, involved over 400,000 men aged 50-69. Just under half received a single invitation for a PSA test as part of the trial.
The University of Bristol and UCL will lead the Population Research UK (PRUK) co-ordination hub, part of an existing strategic investment from the UKRI Infrastructure Fund.
New research has found no evidence of a difference between recovery time and complications when comparing standard and keyhole surgical incisions for the treatment of oesophageal cancer (cancer of the gullet). The study, led by the University of Bristol Medical School and published in the British Journal of Surgery, showed surgeons treating patients with oesophageal cancer do not need to change their practice if they have a strong preference for either procedure type.
